Search

Author/Creator Smolen, J S

1. 060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. (12th April 2019)

Authors:
Smolen, J S; Cohen, S; Emery, P; Rigby, W; Tanaka, Y; Zhang, Y; Friedman, A; Othman, A A; Camp, H S; Pangan, A L
Journal:
Rheumatology
Issue:
Volume 58(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Abatacept (CTLA-4Ig) therapy prevents activation induced cell death (AICD) of regulatory T cells and reduces the susceptibility of T cells to regulatory T cell suppression in patients with rheumatoid arthritis (RA). (22nd February 2012)

Authors:
Bonelli, M; Göschl, L; Blüml, S; Smolen, J S; Scheinecker, C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 1
Page Start:
A10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗